IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction.

Autor: Vernia, Filippo1 (AUTHOR) filippo.vernia1@gmail.com, Monaco, Sabrina1 (AUTHOR), Latella, Giovanni1 (AUTHOR) giovanni.latella@univaq.it
Zdroj: Journal of Clinical Medicine. Jul2024, Vol. 13 Issue 14, p3993. 18p.
Databáze: Academic Search Ultimate